[{"Assets_0_Q3_USD":4170339.0,"CommonStockSharesOutstanding_0_Q3_shares":12039912.0,"EarningsPerShareBasic_1_Q3_USD":-0.16,"EarningsPerShareBasic_3_Q3_USD":-0.39,"EarningsPerShareDiluted_1_Q3_USD":-0.16,"EarningsPerShareDiluted_3_Q3_USD":-0.39,"NetCashProvidedByUsedInOperatingActivities_3_Q3_USD":-5450024.0,"NetIncomeLoss_1_Q3_USD":-1981494.0,"NetIncomeLoss_3_Q3_USD":-4652904.0,"StockholdersEquity_0_Q3_USD":2802032.0,"WeightedAverageNumberOfDilutedSharesOutstanding_1_Q3_shares":12035912.0,"WeightedAverageNumberOfDilutedSharesOutstanding_3_Q3_shares":12035720.0,"WeightedAverageNumberOfSharesOutstandingBasic_1_Q3_shares":12035912.0,"WeightedAverageNumberOfSharesOutstandingBasic_3_Q3_shares":12035720.0,"Ticker":"RLMD","CIK":"1553643","name":"RELMADA THERAPEUTICS, INC.","OfficialName":"Relmada Therapeutics Inc. Common Stock","form":"10-Q","period":"20170331","fy":"2017.0","fp":"Q3","qtrs":"0","uom":"USD","footnote":"nan","Market Cap":"772606380.0","Country":"United States","Sector":"Health Care","Industry":"Biotechnology: Pharmaceutical Preparations","Market":"NASDAQ","SP500":"nan","filed":"20170515"}]